Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
8.13
0.00 (0.00%)
At close: Jun 27, 2025, 4:00 PM
8.13
0.00 (0.00%)
After-hours: Jun 27, 2025, 4:34 PM EDT
Amneal Pharmaceuticals Revenue
Amneal Pharmaceuticals had revenue of $695.42M in the quarter ending March 31, 2025, with 5.50% growth. This brings the company's revenue in the last twelve months to $2.83B, up 13.42% year-over-year. In the year 2024, Amneal Pharmaceuticals had annual revenue of $2.79B with 16.73% growth.
Revenue (ttm)
$2.83B
Revenue Growth
+13.42%
P/S Ratio
0.89
Revenue / Employee
$340,986
Employees
8,300
Market Cap
2.55B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.79B | 400.35M | 16.73% |
Dec 31, 2023 | 2.39B | 181.30M | 8.20% |
Dec 31, 2022 | 2.21B | 118.64M | 5.67% |
Dec 31, 2021 | 2.09B | 101.15M | 5.08% |
Dec 31, 2020 | 1.99B | 366.15M | 22.51% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
AMRX News
- 2 days ago - Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences - GlobeNewsWire
- 15 days ago - Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension - GlobeNewsWire
- 4 weeks ago - Amneal to Participate at Upcoming Investor Conferences in June - GlobeNewsWire
- 6 weeks ago - US FDA approves Amneal's migraine treatment - Reuters
- 6 weeks ago - Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults - GlobeNewsWire
- 7 weeks ago - Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S. - GlobeNewsWire
- 2 months ago - Amneal Pharmaceuticals, Inc. (AMRX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Amneal Reports First Quarter 2025 Financial Results - Business Wire